Xenon Pharmaceuticals’ 2026 Q2 Call: Revenue Guidance, Academic Market, and Data Timeline Contradictions Emerge

Date of Call: Aug 6, 2026

Guidance:

• NDA submission for AZK on track for Q3 2025.
• First Phase III MDD study (ExNova 2) results expected in first half of 2027.
• Phase I studies for XEN1120 and XEN1701 in pain nearing completion, with Phase II proof-of-concept designs pending.
• XEN1720 (NAV1.7) Phase I study initiated.
• Sufficient cash to fund operations into 2029.

Business Commentary:

Progress in NDA Submission and Commercial Readiness:

• Xenon Pharmaceuticals is on track to submit the NDA for AZK later in the quarter, following a successful pre-NDA meeting with the FDA.
• The positive feedback from healthcare providers and the collaborative nature of the FDA meeting contributed to this progress.

XTOL2 Trial Results and Market Feedback:

• The company presented the XTOL2 results at major conferences, showing the best placebo-adjusted response in pivotal focal seizure studies.
• The strong efficacy and safety profile of AZK, as well as its rapid onset of action, generated excitement and positive feedback from the epilepsy community.

Pain Program Advancements:

• Xenon is nearing completion of Phase I studies for XEN-1120 and XEN-1701, and has initiated clinical development for a second NAV1.7 molecule, XEN-1720.
• The progress in pain programs is driven by the critical unmet need for non-opioid therapies and the strong genetic validation of the NAV1.7 target.

Neuropsychiatry Pipeline Expansion:

• The company is advancing three Phase III studies for AZK in major depressive disorder and bipolar depression.
• The expansion into neuropsychiatry is supported by strong preclinical and clinical rationale for KV7 openers, with results expected in the first half of 2027.

Financial Position and Strategic Investments:

• Xenon reported $1.2 billion in cash, cash equivalents, and marketable securities, providing funding into 2029.
• The strong financial position allows the company to support the U.S. launch of AZK, multiple registration programs, and the continued development of its pain pipeline.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed excitement about pipeline progress, stating 'another productive quarter' and 'very positive' FDA pre-NDA meeting. AZK's 'best placebo-adjusted efficacy' and 'differentiated profile' generated 'very positive feedback' and confidence in becoming a 'preferred add-on therapy.' The company is 'well positioned' for launch and 'optimistic about the opportunity ahead.'

Q&A:

• Question from Paul: Concerns about shipping above consumption... (rephrased: Recapping the FDA pre-NDA meeting and notable outcomes, and providing update on pain program.
  Response: Pre-NDA meeting was productive and collaborative, with alignment on NDA package components and submission on track for Q3. For pain programs, data supports exposure and receptor occupancy for efficacy, with Phase I nearing completion and Phase II designs in progress.

• Question from Tess Romero (J.P. Morgan): Thoughts on what additional XTOL2 data to disclose and publication strategy.
  Response: Strategy involves peer-reviewed publication of XTOL2 data to support epilepsy community understanding, with more analysis to come; data will be presented at upcoming conferences like AES.

• Question from Matt Barcus (Jefferies): Details on Phase 1 pain study updates, data to share, acute pain indications, and timing for XSEED interim look.
  Response: Phase I studies nearing completion; data will inform decision to advance to Phase II proof-of-concept. ExNova 2 data expected first half 2027, with ExNova 3 and XSEED (BPD) readouts to follow later.

• Question from Brian Abrahams (RBC Capital Markets): Characterizing pricing benchmarks for AZK and payer receptivity to premium pricing, and commercial strategy if a KB7 fast follower emerges.
  Response: Payer discussions focus on re-educating about focal seizures and unmet need; AZK's novel mechanism and profile set a high bar. Pricing work ongoing, with value proposition centered on efficacy, safety, and patient access.

• Question from Kevin Strang (Goldman Sachs): Rationale for KB7 in MDD and specific efficacy signals expected from ExNova 2.
  Response: KB7's novel mechanism, potential impact on anhedonia, rapid onset, and differentiated tolerability (e.g., no sexual dysfunction/weight gain) are key attributes driving interest in MDD, with focus on overall profile over specific efficacy thresholds.

Contradiction Point 1

Q3 Revenue Guidance Step-Down Explanation

Contradiction on the primary driver for the Q3 revenue step-down.

Luke Sergott (Barclays) - Luke Sergott (Barclays)

2026Q2: The Q3 outlook is consistent with the Q1 call and reflects the peak transition dynamics in spatial. As customers anticipate Atera, they are moderating purchases of existing spatial instruments and consumables, leading to a 'modest couple million dollar step down' from Q2 to Q3. - [Adam Paige](A)

What factors contributed to the Q3 revenue guide step-down and the Q4 revenue step-up beyond the Atera launch and Apex Flex? - Kyle Mikson (Canaccord)

2026Q2: The constraint for Atera shipments is manufacturing capacity, not demand, which is 'extraordinary.' The team is working to ramp production to meet future demand. - [Serge Shakhtanov](S)

Contradiction Point 2

Characterization of the Academic End-Market

Contradiction on the health and near-term outlook of the academic purchasing environment.

Is Jayden from JP Morgan participating on behalf of Casey Woodring in the earnings call? - Jayden (JP Morgan, on for Casey Woodring)

2026Q2: The academic environment remains 'tenuous' despite improved sentiment. Funding dollars are not flowing through to purchasing decisions... The guidance assumes the macro stays the same, with no anticipated near-term improvement. - [Serge Shakhtanov](S)

How are academic end-market trends, including the translation of grant approvals into purchasing activity, impacting guidance, and is there potential upside if the academic environment improves? - Thomas (Guggenheim Securities, on for Subbu Nambi)

2026Q2: Demand is strong, and few customers are lobbying to delay orders. The company has extensive experience launching game-changing platforms and has done 'a lot of testing' on Atera before shipping. - [Serge Shakhtanov](S)

Contradiction Point 3

Timeline and Plan for Sharing Phase I Pain Study Data

Contradiction on when and how Phase I pain data will be disclosed to the public.

Matt Barcus (Jefferies) - Matt Barcus (Jefferies)

2026Q2: As the Phase 1 studies near completion, the company will share the full data package, which is expected to support progression to Phase 2 proof-of-concept studies in acute pain. - [Tucker Kelly](CFO) & [Ian Mortimer](CEO)

What additional data from the Phase 1 pain studies will be shared this year, the acute pain indications being pursued, and the timeline for interim data from the Exceed study (Bipolar Depression) following the ExNova 2 (MDD) readout in H1 2027? - Cory Kasimov (Evercore)

2026Q1: The phase I studies for both pain programs... will complete later this year. The company will share that it has achieved sufficient receptor occupancy and exposure to warrant a phase II proof-of-concept study. Whether detailed phase I data is presented publicly is still to be determined. - [Ian Mortimer](CEO)

Contradiction Point 4

ExNova 2 (MDD) Study Powering Assumptions and Design

Contradiction on the primary efficacy endpoint and statistical powering for the MDD Phase 3 trial.

Kevin Strang (Goldman Sachs) - Kevin Strang (Goldman Sachs)

2026Q2: The study is adequately powered to detect a clinically meaningful separation (about 2-2.5 points) on the HAMD-17 scale, with a sample size of 450 patients. - [Darren Klein](CCO) & [Dr. Chris Kenney](CMO)

What are the powering assumptions for the HAMD-17 in the ExNova 2 study, have there been any changes in baseline depression severity from Phase 2 to Phase 3, and what is the expected adoption timeline for general neurologists for AZK along with the planned education efforts? - Matt Barcus (Jefferies) - Follow-up

2026Q1: For MDD, the focus is less on a specific statistical separation threshold and more on the overall patient profile. - [Dr. Chris Kenney](CMO) & [Darren Klein](CCO)

Contradiction Point 5

Timeline and Strategy for Sharing/Publishing XTOL2 Data

Inconsistent statements on when and how key Phase 3 data will be disclosed.

Tess Romero (J.P. Morgan) - Tess Romero (J.P. Morgan)

2026Q2: A significant amount of key efficacy and safety data from XTOL2 has already been shared... Peer-reviewed publications of the XTOL and XTOL-LE (long-term extension) data are in progress, and the team is working to get the XTOL2 data peer-reviewed as well to further support the epilepsy community. - [Darren Klein](CCO) & [Dr. Chris Kenney](CMO)

What is the strategy for sharing data from the Phase 3 XTOL2 trial and future publications? - Paul Matteis (Stifel)

20251104-2025 Q3: Top-line data will include key efficacy endpoints and overall safety/tolerability, similar to the previous X-TOLE release. The critical path for the NDA is the efficacy results from X-TOLE2. Much of the NDA preparation is already underway, integrating X-TOLE2 data with existing clinical data. - [Ian Mortimer](CEO), [Christopher Kenney](CMO)